hpk1-in-3

HPK1-IN-3 is a selective, potent, ATP-competitive inhibitor of hematopoietic progenitor cell kinase 1 (HPK1; MAP4K1) (IC50: 0.25 nM). HPK1-IN-3 has IL-2 cellular potency and is able to act on human peripheral blood mononuclear cells (PBMC) with an EC50 value of 108 nM.

HPK1-IN-36 (compound 2) is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), demonstrating an inhibitory concentration 50 (IC50) of 0.5 nM [1].

HPK1-IN-34 (Compound 143) is an inhibitor of HPK1 (Haematopoietic progenitor kinase 1) with an IC₅₀ < 0.1 μM, suitable for cancer and immunology research.

HPK1-IN-30 is a potent inhibitor of HPK1 with potential applications in cancer disease research.

HPK1-IN-33 (compound 21), a Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor, exhibits a high potency with a K_i of 1.7 nM. It effectively inhibits IL-2 production, demonstrating EC_50 values of 286 nM in Jurkat WT cells and >10000 nM in Jurkat HPK1 KO cells [1].

HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .

HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM. This compound reduces p-SLP76 expression and facilitates the secretion of IL-2 [1].

HPK1-IN-39 (Compound 10n), a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) with an inhibitory concentration (IC50) of 29 nM, impedes the phosphorylation of SLP76. This compound is applicable in the research of cancer immunotherapy [1].

HPK1-IN-37 (compound A85) is a potent HPK1 inhibitor with an IC50 value of 3.7 nM, suitable for research on HPK1-associated diseases and disorders, particularly cancers [1].

AZ3246 is an orally active, selective inhibitor of HPK1 with an IC50 of less than 3 nM. It induces IL-2 secretion in T cells with an EC50 of 90 nM. AZ3246 also functions as a low-volume, low-clearance antitumor compound.

HPK1-IN-45 (Compound 3) is an HPK1 inhibitor with an IC50 of 0.3 nM. It hinders the phosphorylation of SLP-76 (IC50= 57.52 nM) and the release of IL-2 (IC50= 38 nM). This compound is applicable in cancer research.

3-Hydroxypropanoic acid-pip-hydroquinone-dihydrouracil is a crucial intermediate in the synthesis of the complete PROTACHPK1 Degrader-2, serving as a conjugate (conjugate) of E3 ligase ligand and linker.